AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

APTAMER GROUP PLC

AGM Information Nov 27, 2025

7491_agm-r_2025-11-27_a8a6dbe5-473d-42ea-a17f-3b2d848b7303.html

AGM Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3251J

Aptamer Group PLC

27 November 2025

27 November 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Results of 2025 Annual General Meeting

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry,  today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 11:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.

Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.

- Ends -

For further information, please contact: 

Aptamer Group plc  

Dr Arron Tolley, Chief Executive Officer
+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser    

Andrew Emmott
+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker    

Andrew Thacker / Guy McDougall
+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations

Sarah Hollins
+44 (0) 113 730 3896

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGLDLFLEFLEFBK

Talk to a Data Expert

Have a question? We'll get back to you promptly.